CHRISTINE ANNE PRATILAS
Medical Practice in New York, NY
License number
New Jersey 25MA07137600
Issued Date
Sep 25, 2000
Expiration Date
Jun 30, 2003
Category
Medical Examiners
Type
Medical Doctor
Address
Address
New York, NY
Personal information
See more information about CHRISTINE ANNE PRATILAS at radaris.comName
Address
Phone
150 E 69Th St APT 3F, New York, NY 10021
150 69Th St, New York, NY 10021
Professional information
Christine Anne Pratilas, New York NY
Specialties:
Pediatric Hematologist / Oncologist
Address:
1275 York Ave, New York, NY 10065
Education:
Doctor of Medicine
Board certifications:
American Board of Pediatrics Certification in Pediatrics, American Board of Pediatrics Sub-certificate in Pediatric Hematology/Oncology (Pediatrics)
Christine Pratilas, New York NY
Work:
Memorial Sloan-Kettering
1275 York Ave, New York, NY 10065
1275 York Ave, New York, NY 10065
Dr. Christine Pratilas, New York NY - MD (Doctor of Medicine)
Specialties:
Pediatric Hematology & Oncology
Age:
49
Address:
MEMORIAL PEDIATRIC GROUP
1275 York Ave, New York 10065
(800) 525-2225 (Phone)
1275 York Ave, New York 10065
(800) 525-2225 (Phone)
Certifications:
Pediatric Oncology & Pediatric Hematology, 2006, Pediatrics, 2010
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
MEMORIAL PEDIATRIC GROUP
1275 York Ave, New York 10065
Memorial Sloan - Kettering Cancer Center
1275 York Ave, New York 10065
1275 York Ave, New York 10065
Memorial Sloan - Kettering Cancer Center
1275 York Ave, New York 10065
Education:
Medical School
Umdnj--Robert Wood Johnson Medical School
Graduated: 1999
Umdnj--Robert Wood Johnson Medical School
Graduated: 1999
Biomarkers For Cancer Treatment
US Patent:
2008013, Jun 5, 2008
Filed:
Apr 2, 2007
Appl. No.:
11/732362
Inventors:
Christine Pratilas - New York NY, US
Neal Rosen - New York NY, US
Neal Rosen - New York NY, US
International Classification:
C12Q 1/68, C07H 21/00, C40B 40/08
US Classification:
435 6, 536 231, 506 17
Abstract:
The present invention provides identification of a thirty-five gene set that predicts the anticancer activity of inhibitors of the RAF/MEK/MAPK pathway, methods of qualifying cancer status in a subject, methods of identifying an anti-tumor response in a subject, methods of monitoring the efficacy of a therapeutic drug in a subject, and methods of identifying an agent useful in the treatment of a cancer based on expression of the thirty-five gene set.